On July 22, 2025, the FDA announced more details on the CNPV pilot program (here), indicating that the Agency will accept no more than five applications for the first year (2025). The announcement provides a broad program overview along with key program benefits. The announcement also outlines the eligibility criteria for inclusion, stating: “Your company […]
In combing through regulations.gov this morning, I found a July 7, 2025 petition (here) submitted by a physician citing concerns about “prematurely expiring drugs.” His point is that many drugs likely would still meet all of the required specifications outlined in an application well past their labeled expiration dates, which could positively impact drug shortages and […]
In this case, it has to do with our blog yesterday (here) and the announcement of how the FDA is embracing “Radical Transparency by Publishing Complete Response Letters.” It turns out that many news outlets jumped on the story as a transformative act, as did we, only to find out that many, if not all, […]
I opened my browser this morning at 6AM PST and the first thing I saw was an FDA notice I never thought I would see. Right there on my computer, the Notice (here) said “FDA Embraces Radical Transparency by Publishing Complete Response Letters”. Yes, that’s right – CRLs are now being posted! According to the […]
The FDA issued a News Release (here) that provides some additional information about the program. “‘Using a common-sense approach, the national priority review program will allow companies to submit the lion’s share of the drug application before a clinical trial is complete so that we can reduce inefficiencies. The ultimate goal is to bring more […]
The newly revised and expanded draft guidance titled Q1 Stability Testing of Drug Substances and Drug Products (here) was published today. This draft guidance represents “a consolidated revision of the ICH Q1A(R2), Q1B, Q1C, Q1D, Q1E, and Q5C series of stability guidances, published November 2003, March 1996, May 1997, January 2003, June 2004, and July […]
An Associated Press article (here) reported that “Food and Drug Administration Commissioner Marty Makary said the agency will aim to review select drugs in one to two months.” This would be accomplished by a team of reviewers similar to those formed under Operation Warp Speed for approvals of the COVID-19 vaccines. “Makary said he will […]
Yesterday, U.S. Senators Markwayne Mullin (R-OK) and Cory Booker (D-NJ) reintroduced the “Prescription Information Modernization Act of 2025.” You’ll likely remember that it has had quite a history. It’s a commonsense bill that would allow firms to use electronic labeling, eliminating the requirement to include paper package inserts, better known as the prescribing information, while […]
Now, here is a head scratcher. According to the Pink Sheet article written by Sue Sutter (here), “The White House requested $6.76bn, a decrease of 3.9%, or $271.5m, from the FY 2025 funding level. The proposal includes $3.17bn in budget authority, a decrease of 11.4%, and $3.59bn in user fees, a 4% increase.” What a dandy, […]
Over the last eight months, a number of priority vouchers were sold by firms that were subject to the award of either a tropical disease priority review voucher, a rare pediatric disease priority review voucher, or a material threat medical countermeasure (MCM) priority review voucher. The purchase prices of these vouchers, while not as high […]
